Results 41 to 50 of about 8,676,773 (167)

Pathophysiological Models of Hypersomnolence Associated With Depression

Biological Psychiatry Global Open Science
Up to 25% of patients with depression experience hypersomnolence (e.g., excessive daytime sleepiness, hypersomnia, and/or sleep inertia), which is associated with treatment resistance, overall poorer outcomes, and safety concerns while driving ...
Christophe Moderie, Diane B. Boivin
doaj   +1 more source

Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof‐Of‐Concept Study of Alixorexton

Journal of Sleep Research, EarlyView.
Orexin 2 receptor agonists have demonstrated that targeting the orexin system may address symptoms of central disorders of hypersomnolence. Results of this phase 1 study support the phase 2 clinical evaluation of oral alixorexton in patients with IH, NT2 and NT1.
Ronald R. Grunstein, Brendon J. Yee, Julia L. Chapman, Jian Eu Tai, Sheila Sivam, Craig Hopkinson, Daniel G. Smith, Alexandra Lovett, Shifang Liu, Sergey Yagoda, Bhaskar Rege   +10 more
wiley   +1 more source

Sodium oxybate therapy for the treatment of alcohol withdrawal syndrome and the maintenance of alcohol abstinence

, 2017
Gamma-hydroxybutyrate (GHB or sodium oxybate) is both an exogenous and endogenous molecule with neuromodulator properties. In the United States, GHB is an approved drug for the treatment of narcolepsy and narcolepsy with cataplexy in adults.
Pichini, Simona, Michele Navarra, Ventura Spagnolo, E, Calapai, Fabrizio, Simona Pichini, Mannucci, Carmen, Gangemi, Sebastiano, Gioacchino Calapai, Navarra, Michele, Sebastiano Gangemi, Elvira Ventura Spagnolo, Calapai, Gioacchino, Carmen Mannucci, Fabrizio Calapai   +13 more
core   +1 more source

Assessing mortality risk in narcolepsy: Evidence from population studies

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 3, September 2026.
Abstract Narcolepsy is a chronic neurologic sleep disorder associated with excessive daytime sleepiness, cataplexy, and a higher prevalence of cardiovascular and psychiatric comorbidities. While these factors may predispose individuals to adverse events, observational studies evaluating mortality in narcolepsy have yielded inconsistent results.
Nawris Alhassan, Susmin Karki, Jagdish Lal   +2 more
wiley   +1 more source

Cerebrospinal fluid orexin testing in Australians with narcolepsy type 1

Internal Medicine Journal, Volume 56, Issue 9, Page 1641-1643, September 2026.
Abstract A clinical diagnosis of narcolepsy type 1 can be challenging, particularly in relation to cataplexy. Despite its specificity, cerebrospinal fluid (CSF) orexin testing is under‐utilised in Australasia. We describe the use of CSF orexin testing in 15 clinically indicated patients from two sleep centres, highlighting its utility in the ...
Mario Fernando, Gianluca Cotta, Samantha Kung, Grace Garden, Jian Eu Tai, Elie Matar, Brendon Yee, Claire Ellender, Sheila Sivam   +8 more
wiley   +1 more source

Effects of low-sodium oxybate on diary-based sleep time in a clinical study in adults with idiopathic hypersomnia

Sleep Medicine
Prolonged nighttime sleep is a prominent symptom in many patients with idiopathic hypersomnia. The only US Food and Drug Administration-approved treatment for idiopathic hypersomnia is low-sodium oxybate (LXB; Xywav®), for which efficacy and safety were established in a double-blind, placebo-controlled, randomized-withdrawal study (NCT03533114).
Morse, Anne Marie, Dauvilliers, Yves, Schneider, Logan, Fuller, Douglas, Steininger, Teresa, Black, Jed, Thorpy, Michael   +6 more
openaire   +3 more sources

iSPHYNCS: Unsupervised Clustering in Questionnaires and Metadata Reveals Distinct Subtypes in the Narcolepsy Borderland

Journal of Sleep Research, Volume 35, Issue 4, August 2026.
Study overview and clustering results in the iSPHYNCS cohort. Participant demographics are summarized in a baseline table. Questionnaire data and metadata were processed through an unsupervised clustering pipeline. A Sankey plot illustrates individual assignment across clusters by diagnostic group.
Rafael Morand, Livia Fregolente, Julia van der Meer, Elena S. Wenz, Annina Helmy, Lorenzo Brigato, Jan D. Warncke, Kseniia Zub, Ramin Khatami, Zhongxing Zhang, Sigrid von Manitius, Silvia Miano, Jens Acker, Mathias Strub, Ulf Kallweit, Gert Jan Lammers, Athina Tzovara, Claudio L. A. Bassetti, Stavroula Mougiakakou, Markus H. Schmidt   +19 more
wiley   +1 more source

Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy

, 2017
This post hoc analysis evaluated the dose-related effects of sodium oxybate on sleep continuity and nocturnal sleep quality in patients with narcolepsy-cataplexy.
Dauvilliers, Yves, Dynin, Efim, Guinta, Diane, Alvarez-Horine, Sarah, Roth, Thomas, Black, Jed   +5 more
core   +1 more source

A Comprehensive Disproportionality Analysis of Drug‐Related Head Injury Reports Using the FAERS Database

Brain and Behavior, Volume 16, Issue 6, June 2026.
ABSTRACT Objective This study aimed to identify and characterize drugs associated with reports of head injury through a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database. Methods A retrospective disproportionality analysis was conducted on FAERS reports from 2004 to 2023.
Jiaqi Guo, Luming Wei, Junfeng Liu, Jimei Zhang, He Wang, Wanjun Lu   +5 more
wiley   +1 more source

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

MedComm, Volume 7, Issue 6, June 2026.
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele, Ajit Manchare, Swapnali Parit, Amol D. Gholap, Krishna Jadhav, Navnath Hatvate, Keshav Raj Paudel, Satish Rojekar   +7 more
wiley   +1 more source